BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
This Quarter Return
+1.23%
1 Year Return
+64.18%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$166M
AUM Growth
+$166M
(-9.5%)
Cap. Flow
-$24.3M
Cap. Flow
% of AUM
-14.65%
Top 10 Holdings %
Top 10 Hldgs %
69.92%
Holding
25
New
8
Increased
3
Reduced
4
Closed
10
Top Buys
| 1 |
BCR
CR Bard Inc.
BCR
|
$11.8M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$11M |
| 3 |
Labcorp
LH
|
$10.9M |
| 4 |
Boston Scientific
BSX
|
$10.8M |
| 5 |
SHPG
Shire pic
SHPG
|
$10.6M |
Top Sells
| 1 |
Biogen
BIIB
|
$12.8M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$12.7M |
| 3 |
WMGI
Wright Medical Group Inc
WMGI
|
$11.9M |
| 4 |
Neurocrine Biosciences
NBIX
|
$11.5M |
| 5 |
Illumina
ILMN
|
$10.8M |
Sector Composition
| 1 | Healthcare | 79.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
| $13.3M | 8.01% |
298,982
-36,018
| -11% | -$1.6M |
|
|
QGENF
2
DELISTED
QIAGEN NV
QGENF
| $12.3M | 7.42% |
438,572
+138,572
| +46% | +$3.88M |
|
|
TSRO
3
DELISTED
TESARO, Inc.
TSRO
| $12.1M | 7.28% |
89,695
-30,305
| -25% | -$4.08M |
|
4
Ironwood Pharmaceuticals
IRWD
$213M
| $11.8M | 7.13% |
772,369
+47,369
| +7% | +$724K |
|
|
BCR
5
DELISTED
CR Bard Inc.
BCR
| $11.8M | 7.1% |
+52,377
| New | +$11.8M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $11M | 6.65% |
+90,134
| New | +$11M |
|
7
Hologic
HOLX
$14.8B
| $11M | 6.62% |
273,478
-31,996
| -10% | -$1.28M |
|
8
Incyte
INCY
$16.8B
| $11M | 6.62% |
109,371
-18,798
| -15% | -$1.88M |
|
|
9
Labcorp
LH
$22.8B
| $10.9M | 6.58% |
+85,000
| New | +$10.9M |
|
|
10
Boston Scientific
BSX
$158B
| $10.8M | 6.5% |
+498,303
| New | +$10.8M |
|
|
SHPG
11
DELISTED
Shire pic
SHPG
| $10.6M | 6.43% |
+62,500
| New | +$10.6M |
|
|
DERM
12
DELISTED
Dermira, Inc.
DERM
| $10.6M | 6.41% |
350,000
+75,000
| +27% | +$2.27M |
|
13
Bristol-Myers Squibb
BMY
$96.5B
| $9.94M | 6% |
+170,000
| New | +$9.94M |
|
14
Edwards Lifesciences
EW
$48B
| $9.65M | 5.83% |
+103,029
| New | +$9.65M |
|
15
ResMed
RMD
$39.7B
| $9M | 5.43% |
+145,000
| New | +$9M |
|
|
16
Biogen
BIIB
$20.5B
| – | – |
-40,996
| Closed | -$12.8M |
|
|
17
BioMarin Pharmaceuticals
BMRN
$11.3B
| – | – |
-137,595
| Closed | -$12.7M |
|
|
18
Illumina
ILMN
$15.5B
| – | – |
-59,270
| Closed | -$10.8M |
|
19
Masimo
MASI
$7.48B
| – | – |
-166,131
| Closed | -$9.88M |
|
|
20
Neurocrine Biosciences
NBIX
$14.1B
| – | – |
-226,501
| Closed | -$11.5M |
|
21
Perrigo
PRGO
$3.23B
| – | – |
-100,000
| Closed | -$9.23M |
|
22
Smith & Nephew
SNN
$16.1B
| – | – |
-325,000
| Closed | -$10.7M |
|
|
MDRX
23
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – |
-600,000
| Closed | -$7.9M |
|
|
NUVA
24
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-129,680
| Closed | -$8.64M |
|
|
WMGI
25
DELISTED
Wright Medical Group Inc
WMGI
| – | – |
-486,180
| Closed | -$11.9M |
|